JW Therapeutics - About the company
JW Therapeutics is a public company based in Shanghai (China), founded in 2016 by James Li. It operates as a Developer of cell immunotherapy products for cancer treatment. JW Therapeutics has raised $200M in funding from investors like Sequoia Capital, Temasek and Mirae Asset. The company has 3280 active competitors, including 1119 funded and 774 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of cell immunotherapy products for cancer treatment. The company's product pipeline includes JWCAR029, JWCAR129, Nex-G for hematologic malignancies, and JWATM203, JWATM204 for solid tumors.
- Website
- jwtherapeutics.com
- Phone Number
- +86 **********
Key Metrics
Founded Year
2016
Location
Shanghai, China
Stage
Public
Total Funding
$200M in 2 rounds
Latest Funding Round
Investors
Ranked
213th among 3280 active competitors
Employee Count
181 as on Jun 30, 2026
Similar Companies
Exit Details
Public
JW Therapeutics's IPO details
JW Therapeutics got listed on Nov 03, 2020.
Click here to take a look at JW Therapeutics's IPO in detail
Sign up to download JW Therapeutics' company profile
JW Therapeutics's funding and investors
JW Therapeutics has raised a total funding of $200M over 2 rounds. Its first funding round was on Mar 07, 2018. Its latest funding round was a Series B round on Jun 30, 2020 for $*****. 10 investors participated in its latest round. JW Therapeutics has 18 institutional investors.
Here is the list of recent funding rounds of JW Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 30, 2020 | 6341726 | Series B | 7101627 | 4757049 | 5209199 | 3009656 |
Mar 07, 2018 | 1702359 | Series A | 2984159 | 7801728 |
Access funding benchmarks and valuations. Sign up today!View details of JW Therapeutics's funding rounds and investors
JW Therapeutics' founders and board of directors
Founder? Claim ProfileHere are the details of JW Therapeutics' key team members:
- James Li: Co-Founder & CEO of JW Therapeutics.
View details of JW Therapeutics's Founder profiles and Board Members
JW Therapeutics' employee count trend
JW Therapeutics has 181 employees as of Jun 26. Here is JW Therapeutics's employee count trend over the years:
Uncover JW Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
JW Therapeutics's Competitors and alternates
Top competitors of JW Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of JW Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 80/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 72/100 | |
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
213th | JW Therapeutics 2016, Shanghai (China), Public | Developer of cell immunotherapy products for cancer treatment | $200M | 59/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on JW Therapeutics's competitors? Click here to see the top ones
JW Therapeutics's Investments and acquisitions
JW Therapeutics has made no investments or acquisitions yet.
News related to JW Therapeutics
Filter this listMedia has covered JW Therapeutics for 1 event in last 1 year, It was about partnerships.
•
•
Carteyva® gets China breakthrough therapy designation for relapsed lymphoma.PR Newswire•Jan 10, 2025•JW Therapeutics
•
•
•
•
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about JW Therapeutics
Explore our recently published companies
- Steemo - Delhi based, 1985 founded, Unfunded company
- SouffleFort - Quebec City based, 2023 founded, Unfunded company
- Wipro Consumer Care - Bengaluru based, 1945 founded, Unfunded company
- Champ Knives - Puchong based, 2014 founded, Unfunded company
- Kansyam - Ahmedabad based, 1990 founded, Unfunded company
- GiantMouse - East Lansing based, 2015 founded, Unfunded company
